DPCO - S. O. 5937(E) 19th December, 2022_New

(Published in Part II, Section 3, Sub-section (ii) of the Gazette of India, Extraordinary)
Government of India
Ministry of Chemicals and Fertilizers
Department of Pharmaceuticals
National Pharmaceutical Pricing Authority
New Delhi, 19th December, 2022
ORDER
S.O. 5937(E):-In exercise of the powers conferred by paragraphs 5, 11 and 15 of the Drugs
(Prices Control) Order, 2013, read with S.O. 1394(E) dated the 30th May, 2013 and S. O. 5249(E)
dated 11th November, 2022 issued by the Government of India in the Ministry of Chemicals and
Fertilizers, the National Pharmaceutical Pricing Authority (hereinafter referred as NPPA), hereby
fixes, the price as specified in column (6) of the table herein below as the retail price, exclusive of
Goods and Services Tax, if any, in relation to the formulation specified in the corresponding entry
in column (2) of the said Table with the strength, unit and name of manufacturer & marketing
company, as specified in the corresponding entries in columns (3), (4) and (5) thereof;
Table
Sl. Name of the Strength Unit Manufacturer & Retail

No. Formulation / Marketing Company Price
Brand Name (Rs.)
(1) (2) (3) (4) (5) (6)
1. Amoxycillin and Each Combi pack contains: M/s Malik Lifesciences 168.43
Potassium (A) Amoxycillin and Pvt. Ltd. / M/s Abbott
Clavulanate Oral Potassium Clavulanate Oral Healthcare Pvt. Ltd.
Suspension IP Suspension IP
Composition:
Each 5ml of Reconstituted
suspension contains:
Combi
Amoxycillin Trihydrate IP eq.
Pack
to Amoxycillin 600mg
Potassium Clavulanate
Diluted IP eq. to Clavulanic
Acid 42.9mg
(B) 2 Ampoule of 25ml each of
Sterile Water for
Reconstitution of Dry Syrup
2. Metformin Each uncoated bilayered M/s Akums Drugs & 11.60
Hydrochloride tablet contains: Pharmaceuticals Ltd. /
(SR), Metformin Hydrochloride IP M/s Abbott Healthcare
Glimepiride and 1000mg (as Sustained 1 Tablet Pvt. Ltd.
Voglibose Release form)
Tablets Glimepiride IP 1mg
Voglibose IP 0.2mg
3. Metformin Each uncoated bilayered M/s Akums Drugs & 13.18
Hydrochloride tablet contains: Pharmaceuticals Ltd. /
(SR), Metformin Hydrochloride IP M/s Abbott Healthcare
Glimepiride and 1000mg (as Sustained 1 Tablet Pvt. Ltd.
Voglibose Release form)
Tablets Glimepiride IP 2mg
Voglibose IP 0.2mg
4. Ceftazidime and Each vial contains: M/s Cipla Limited 2500.00
Avibactam Ceftazidime (pentahydrate) IP Per Vial
powder for eq. to Ceftazidime 2mg
Sl. Name of the Strength Unit Manufacturer & Retail
No. Formulation / Marketing Company Price
Brand Name (Rs.)
(1) (2) (3) (4) (5) (6)
concentrate for Avibactam Sodium eq. to
solution for Avibactam 0.5gm
infusion Sodium content approx.
148mg (6.4meq)/vial
5. Moxifloxacin Composition: M/s Pure and Cure 27.43
Hydrochloride Moxifloxacin Hydrochloride IP Healthcare Pvt. Ltd. /
and Loteprednol eq. to Moxifloxacin 0.5% w/v M/s Cipla Limited
Ophthalmic Loteprednol Etabonate 0.5% Per ml
Suspension w/v (Sterile & Micronized)
Sterile aqueous buffered
vehicle q.s.
6. Itraconazole Each hard gelatin capsule M/s Ravenbhel 11.60
Capsules 65mg contains: Healthcare Pvt. Ltd. /
1
(Supra- Itraconazole BP 65mg M/s Mankind Pharma
Capsule
Bioavailable Ltd.
Formulation)
7. Acetylcysteine & Each film coated tablet M/s Pure and Care 14.91
Acebrophylline contains: Healthcare Pvt. Ltd. /
Tablets Acetylcysteine BP 600mg 1 Tablet M/s Cadila
Acebrophylline 100mg Pharmaceuticals
Limited
8. Paracetamol, Each uncoated tablet M/s Dallas Drugs Pvt. 2.76
Phenylephrine contains: Ltd. / M/s Micro Labs
Hydrochloride, Paracetamol IP 500mg Pvt. Ltd.
Caffeine & Phenylephrine HCl IP 5mg 1 Tablet
Diphenhydramin Caffeine IP 30mg
e Hydrochloride Diphenhydramine HCl IP
Tablets 25mg
9. Rabeprazole Each Enteric coated tablet M/s Dallas Drugs Pvt. 5.90
and contains: Ltd. / M/s Micro Labs
Ondansetron Rabeprazole Sodium IP 20mg 1 Tablet Pvt. Ltd.
tablets Ondansetron Hydrochloride
IP eq. to Ondansetron 4mg
10. Amoxycillin and Each 5ml of Reconstituted M/s Malik Lifesciences 168.43
Potassium suspension contains: Pvt. Ltd. / M/s
Clavulanate Oral Amoxycillin Trihydrate IP eq. Zuventus Healthcare
Per Vial
Suspension IP to Amoxycillin 600mg Limited
(50ml)
Potassium Clavulanate
Diluted IP eq. to Clavulanic
Acid 42.9mg
Note:
(a) The manufacturer of above-mentioned formulations i.e., “new drug” under paragraph
2(1)(u) of the DPCO, 2013 shall fix the retail price as specified in column (6) of the table
hereinabove.
(b) The manufacturer may add Goods and Services Tax only if they have paid actually or it is
payable to the Government on the retail price mentioned in column (6) of the above said
table.
(c) The retail price for a pack of the aforesaid formulation shall be arrived at by the concerned
manufacturer in accordance with the retail price specified in column (6) of the above table
as per provisions contained in paragraph 11 of the DPCO, 2013. The manufacturer shall
issue a price list in Form–V from date of Notification as per paragraph 24 of the DPCO,
2013 to NPPA through IPDMS and submit a copy to State Drug Controller and dealers.
(d) As per para 24(4) of DPCO 2013, every retailer and dealer shall display price list and the
supplementary price list, if any, as furnished by the manufacturer, on a conspicuous part of
the premises where he carries on business in a manner so as to be easily accessible to any
person wishing to consult the same.
(e) The above mentioned retail price is applicable only to the individual manufacturer /
marketer as mentioned above i.e. who have applied for the same by submitting Form-I for
price fixation / revision as stipulated under DPCO, 2013 and subject to fulfilment of all the
applicable statutory requirements as laid down by the Govt. under relevant statutes/ rules,
including manufacturing license permission from the Competent Authority i.e. the
Central/State Licensing Authority, as may be applicable, by the concerned
manufacturer/marketing companies.
(f) In case the retail price of any of the aforesaid formulations is not complied with, as per
instant price notification and notes specified hereinabove, then the concerned
manufacturer/marketing company shall be liable to deposit the overcharged amount along
with the interest thereon under the provisions of the DPCO, 2013 read with the Essential
Commodities Act, 1955.
(g) Consequent to the fixation of retail price of such formulation as specified in column (2) of
the above table with the strength and name of Manufacturer & Marketing Companies
specified in the corresponding entries in Column (3) & (5) thereof, the price order(s) fixing
the retail price of the formulation with specified strength for that Manufacturer & Marketing
Companies as specified in corresponding entries in Column (2), (3) and (5) thereof, if any,
issued prior to this notification, stand(s) superseded.
PN/237/105/2022/F F. No. 8(105)/2022/D.P./NPPA-Div.-II
(Mahaveer Saini)
Deputy Director

DPCO - S. O. 5937(E) 19th December, 2022_New

Uploaded by

Copyright:

Available Formats

DPCO - S. O. 5937(E) 19th December, 2022_New

Uploaded by

Document Information

Copyright

Available Formats

Share this document

Share or Embed Document

Sharing Options

Did you find this document useful?

Is this content inappropriate?

Copyright:

Available Formats

DPCO - S. O. 5937(E) 19th December, 2022_New

Uploaded by

Copyright:

Available Formats

(Published in Part II, Section 3, Sub-section (ii) of the Gazette of India, Extraordinary)

New Delhi, 19th December, 2022

Sl. Name of the Strength Unit Manufacturer & Retail

PN/237/105/2022/F F. No. 8(105)/2022/D.P./NPPA-Div.-II

You might also like